{
  "$schema": "folio-library-entry/v1",
  "id": "10665-349550",
  "blocks": [
    {
      "id": "library/10665-349550/blocks/prose-page-001",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 1",
      "pageStart": 1,
      "pageEnd": 1,
      "target": "../sections/page-001.md",
      "narrative": null,
      "content": "GUIDANCE\nMONITORING AND EVALUATION\nGLOBAL GUIDANCE ON \nCRITERIA AND PROCESSES FOR VALIDATION:\nELIMINATION OF \nMOTHER-TO-CHILD \nTRANSMISSION OF \nHIV, SYPHILIS AND \nHEPATITIS B VIRUS\n2021",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "The cover page of the 2021 WHO global guidance on criteria and processes for validating elimination of mother-to-child transmission of HIV, syphilis and hepatitis B virus.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-349550/blocks/prose-page-002",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 2",
      "pageStart": 2,
      "pageEnd": 2,
      "target": "../sections/page-002.md",
      "narrative": null,
      "content": "_(no text on this page)_",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "A blank page with no text.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-349550/blocks/prose-page-003",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 3",
      "pageStart": 3,
      "pageEnd": 3,
      "target": "../sections/page-003.md",
      "narrative": null,
      "content": "GLOBAL GUIDANCE ON \nCRITERIA AND PROCESSES FOR VALIDATION:\nELIMINATION OF \nMOTHER-TO-CHILD \nTRANSMISSION OF \nHIV, SYPHILIS AND \nHEPATITIS B VIRUS\n2021",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "The inner title page of the 2021 global guidance on validating elimination of mother-to-child transmission of HIV, syphilis and hepatitis B.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-349550/blocks/prose-page-004",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 4",
      "pageStart": 4,
      "pageEnd": 4,
      "target": "../sections/page-004.md",
      "narrative": null,
      "content": "Global guidance on criteria and processes for validation: elimination of mother-to-child \ntransmission of HIV, syphilis and hepatitis B virus\nThis publication is the update of the document published in 2017 entitled “Global guidance on criteria and \nprocesses for validation: elimination of mother-to-child transmission of HIV and syphilis, second edition”.\nISBN 978-92-4-003936-0 (electronic version)\nISBN 978-92-4-003937-7 (print version)\n© World Health Organization 2021\nSome rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-\nShareAlike 3.0 IGO licence",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "The copyright and cataloguing page of the 2021 EMTCT validation guidance, noting it updates the 2017 edition and giving ISBNs, licence terms and disclaimers.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-349550/blocks/prose-page-005",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 5",
      "pageStart": 5,
      "pageEnd": 5,
      "target": "../sections/page-005.md",
      "narrative": null,
      "content": "CONTENTS\nFOREWORD\t\niv\nACKNOWLEDGEMENTS\t\nvi\nESSENTIAL WHO EMTCT RESOURCES\t\nviii\nABBREVIATIONS AND ACRONYMS\t\nix\nGLOSSARY\t\nx\nEXECUTIVE SUMMARY\t\nxiii\n1.\tINTRODUCTION\t\n1\n\t 1.1.\t \u0007MOTHER-TO-CHILD TRANSMISSION IN THE \t\n1 \nHIV, SYPHILIS AND HBV EPIDEMICS\n\t 1.2.\t \u0007TRIPLE ELIMINATION OF MOTHER-TO-CHILD \t 3 \nTRANSMISSION AND ITS VALIDATION\n\t 1.3.\t STANDARD CRITERIA AND PROCESSES\t\n4\n2.\t\u0007RATIONALE FOR STANDARDIZED CRITERIA \t\n7 \nAND PROCESSES FOR EMTCT OF HIV,  \nSYPHILIS AND HBV\t\n\t 2.1.\t \u0007QUALIFYING REQUIREMENTS FOR EMTCT \t\n7 \nOF HIV, SYPHILIS AND HBV\t\n\t 2.2.\t \u0007STANDARDIZED CRITERIA USED IN EMTCT\t\n8  \nOF HI",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "The table of contents of the EMTCT validation guidance, listing chapters on rationale, indicators and targets, validation processes and annexes on measuring HBV indicators.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-349550/blocks/prose-page-006",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 6",
      "pageStart": 6,
      "pageEnd": 6,
      "target": "../sections/page-006.md",
      "narrative": null,
      "content": "The global community has committed to eliminating mother-to-child transmission (EMTCT), also \nknown as vertical transmission, of HIV and syphilis as a public health priority. In 2014 the World \nHealth Organization (WHO) released the first edition of the Global guidance on criteria and \nprocesses for validation: elimination of mother-to-child transmission of HIV and syphilis. In 2015 the \nGlobal Validation Advisory Committee for EMTCT was established and that same year the first country, \nCuba, was validated. The second edition of the guidance, published in 2017, captured the learning \nfrom val",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "A foreword recounting the history of global efforts to validate elimination of mother-to-child transmission of HIV and syphilis since 2014, including Cuba's validation in 2015. It stresses human rights and the involvement of women living with HIV or HBV in services.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-349550/blocks/prose-page-007",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 7",
      "pageStart": 7,
      "pageEnd": 7,
      "target": "../sections/page-007.md",
      "narrative": null,
      "content": "Foreword\nThis third version of the EMTCT global validation guidance document provides standardized \nprocesses and consensus-developed criteria to validate EMTCT of HIV, syphilis and HBV and to \nrecognize high burden countries that have made significant progress on the Path to Elimination.  \nThe guidance strongly emphasizes country-led accountability, rigorous analysis, intensive \nprogramme assessment and multilevel collaboration, including the involvement of communities  \nof women living with HIV or HBV. A harmonized approach to triple elimination is encouraged, but, \ndepending on readiness, c",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Continuation of the foreword, explaining that this third version sets standard criteria for validating triple elimination and recognising high-burden countries on the Path to Elimination, signed by the WHO HIV, hepatitis and STI programmes director.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-349550/blocks/prose-page-008",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 8",
      "pageStart": 8,
      "pageEnd": 8,
      "target": "../sections/page-008.md",
      "narrative": null,
      "content": "ACKNOWLEDGEMENTS\nThis guidance document is the result of collaboration between the WHO Global HIV, Hepatitis  \nand STI Programmes, led by their Director, Meg Doherty, the Global Validation Advisory Committee \nfor elimination of mother-to-child transmission (GVAC) members and observers, WHO counterpart \nprogrammes at the regional and country levels, and contributing member states.\nMany professionals from a range of backgrounds and specialties have contributed to the development \nof this guidance. WHO is sincerely grateful for their time and support. The third version was developed \nthrough thre",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Acknowledges the WHO programmes, Global Validation Advisory Committee members and others who developed the guidance, describing how the third version was produced through virtual meetings and consultation.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-349550/blocks/prose-page-009",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 9",
      "pageStart": 9,
      "pageEnd": 9,
      "target": "../sections/page-009.md",
      "narrative": null,
      "content": "Acknowledgements\nPast and current advisors and EMTCT focal points from the six WHO regions contributed to \nthe guidance revision based on the experiences from national and regional EMTCT validation \ncommittees, secretariats and teams. African Region: Francoise Bigirimana, Innocent Nuwagira. \nRegion of the Americas: Sandra Jones, Leandro Sereno, Massimo Ghidinelli. South-East Asia \nRegion: Mukta Sharma, B.B. Rewari. European Region: Nicole Seguy, Elena Vovc, Antons \nMozalevskis. Eastern Mediterranean Region: Joumana George Hermez, Bridget Akora \nMugisa. Western Pacific Region: Naoko Ishikawa, A",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Continues the acknowledgements, naming regional EMTCT focal points and WHO staff and noting PEPFAR funding through CDC and USAID.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-349550/blocks/prose-page-010",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 10",
      "pageStart": 10,
      "pageEnd": 10,
      "target": "../sections/page-010.md",
      "narrative": null,
      "content": "Additional information on EMTCT of HIV, syphilis and HBV, including updated tools and other \nguidance, are available on the WHO websites:\nTriple elimination initiative of EMTCT of HIV, syphilis and HBV\nhttps://www.who.int/initiatives/triple-elimination-initiative-of-mother-to-child-transmission-of-hiv-\nsyphilis-and-hepatitis-b/validation\nEMTCT validation processes and tools\nhttps://www.who.int/initiatives/triple-elimination-initiative-of-mother-to-child-transmission-of-hiv-\nsyphilis-and-hepatitis-b/validation/process-and-tools\nRegional EMTCT websites\nWHO Regional Office for Africa\nhttp://www.a",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Lists essential WHO web resources on triple elimination, validation processes, regional websites and related guidance.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-349550/blocks/prose-page-011",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 11",
      "pageStart": 11,
      "pageEnd": 11,
      "target": "../sections/page-011.md",
      "narrative": null,
      "content": "ABOs\t\nadverse birth outcomes\nANC\t\nantenatal care\nART\t\nantiretroviral therapy\nARV\t\nantiretroviral\nCDC\t\n\u0007United States Centers for Disease  \nControl and Prevention \nCHB\t\nchronic hepatitis B\nCS\t\ncongenital syphilis\nCSF\t\ncerebrospinal fluid \nEID\t\nearly infant diagnosis\nEMTCT\t\n\u0007elimination of mother-to-child \ntransmission\nEQA\t\nexternal quality assurance\nFPC \t\nfinite population correction\nGAM\t\nUNAIDS Global AIDS Monitoring \nGHSS\t\nglobal health sector strategy\nGIPA\t\n\u0007greater involvement of people \nliving  \nwith HIV/AIDS\nGMEF\t\n\u0007Global Multi-disease Elimination \nFramework\nHBeAg\t\nhepatitis B e antigen\nH",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "A list of abbreviations and acronyms used in the guidance.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-349550/blocks/prose-page-012",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 12",
      "pageStart": 12,
      "pageEnd": 12,
      "target": "../sections/page-012.md",
      "narrative": null,
      "content": "The following glossary definitions are sourced from current relevant WHO guidelines (1-5). \nAdequate treatment of syphilis: The treatment of seropositive women with at least one \ndose of intramuscular benzathine penicillin G at least 30 days prior to delivery is the minimum time \nnecessary to prevent transmission of syphilis to the infant. Ideally, maternal treatment should be \ngiven in the first trimester, or as early as possible if antenatal care (ANC) is started later.\nEarly infant diagnosis: The testing of HIV-exposed infants before two months of age, to \nestablish timely diagnosis and acc",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Glossary entries taken from WHO guidelines, defining terms such as adequate syphilis treatment, early infant diagnosis and informed consent.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-349550/blocks/prose-page-013",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 13",
      "pageStart": 13,
      "pageEnd": 13,
      "target": "../sections/page-013.md",
      "narrative": null,
      "content": "Glossary\nIntegrated service delivery: Health services that are managed and delivered in a way that \nensures that people receive a continuum of health promotion, infection prevention, diagnosis, \ntreatment, disease management, rehabilitation and palliative care services at the different levels \nand sites of care within the health system and according to their needs throughout the life-course. \nIntegration: The co-location and sharing of services and resources across different health \nservice delivery areas. This may include the provision of HIV, syphilis and HBV testing, prevention, \ntreatment",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Further glossary definitions, covering terms such as integrated service delivery, integration, quality assurance and quality control.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-349550/blocks/prose-page-014",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 14",
      "pageStart": 14,
      "pageEnd": 14,
      "target": "../sections/page-014.md",
      "narrative": null,
      "content": "Quality management system: A system to direct and control an organization with regard  \nto quality. Systematic and process-oriented efforts are essential to meet quality objectives. \nRapid diagnostic test (RDT): Immunoassays that detect antibodies or antigens and can give a \nresult in less than 30 minutes. Most RDTs can be performed with capillary whole blood collected by \nfinger-stick sampling and some, by oral fluid sampling. \nTesting algorithm: When specific products are populated into a testing strategy. A specific \nproduct is defined with a product name, product code(s), a manufacturing s",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "The final glossary entries, defining terms such as quality management system, rapid diagnostic test, testing algorithm and validation.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-349550/blocks/prose-page-015",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 15",
      "pageStart": 15,
      "pageEnd": 15,
      "target": "../sections/page-015.md",
      "narrative": null,
      "content": "The global community has committed to the elimination of mother-to-child transmission (MTCT), \nalso referred to as vertical transmission, of HIV, syphilis and hepatitis B virus (HBV) as a public health \npriority. The global commitment to EMTCT was established due to the continued high global burden \nof mother-to-child (MTCT), or vertical transmission, of these infections. The purpose of the elimination \ngoal is to ensure the availability of quality reproductive and maternal and child health (MCH) services \nto reduce and control the transmission of HIV, syphilis and HBV between mothers and thei",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Opens the executive summary by describing the global commitment to eliminate vertical transmission of HIV, syphilis and HBV and the purpose of the goal. It cites 2030 targets including zero new infant HIV infections and HBsAg prevalence of 0.1% or less in young children.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-349550/blocks/prose-page-016",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 16",
      "pageStart": 16,
      "pageEnd": 16,
      "target": "../sections/page-016.md",
      "narrative": null,
      "content": "In 2014 WHO led a global consultation that resulted in the first edition of Global guidance on \ncriteria and processes for validation: elimination of mother-to-child transmission of HIV and syphilis, \nalso known as the “Orange Book”. This guidance document supported the standardization and \nformal approach to EMTCT validation, including criteria, indicators and targets to be achieved. \nThese formed the basis for foundational requirements for validation in the four areas of (i) data,  \n(ii) laboratory, (iii) programme and (iv) human rights, gender equality and community engagement. \nA second ed",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Recounts the development of the EMTCT validation guidance from the 2014 \"Orange Book\" through later editions, with requirements in data, laboratory, programme and human rights areas. It introduces a summary table of targets.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-349550/blocks/prose-page-017",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 17",
      "pageStart": 17,
      "pageEnd": 17,
      "target": "../sections/page-017.md",
      "narrative": null,
      "content": "Executive summary\nTable 1. \u0007Summary of impact and process/programmatic targets \nfor EMTCT of HIV, syphilis and HBV\nElimination targets\nHIV EMTCT\nSyphilis EMTCT\nHBV EMTCT\n2030 WHO GHSS (8, \n10, 11) and UNGA \npolitical declaration \n(13) aspirational \ntargets \nZero new infections \namong infants and young \nchildren and achievement \nof the 95-95-95 targets \n≤50 cases of CS per  \n100 000 live births in \n80% of countries \n95% reduction in \nincidence of chronic HBV \ninfections\nEMTCT impact targets\nA population case rate \nof new paediatric HIV \ninfections due to MTCT \nof ≤50 cases per 100 000 \nlive bir",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "A table summarising impact and programme targets for eliminating mother-to-child transmission of HIV, syphilis and HBV, from 2030 global targets to specific validation thresholds, with explanatory footnotes.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-349550/blocks/table-001",
      "types": [
        "folio-assistant-core:Table",
        "doco:Table"
      ],
      "kind": "table",
      "title": "Table 1. Summary of impact and process/programmatic targets for EMTCT of HIV, syphilis and HBV",
      "pageStart": 17,
      "pageEnd": 17,
      "target": "../tables/table-1.csv",
      "narrative": "draft",
      "content": "The table summarizes, for the elimination of mother-to-child transmission (EMTCT) of HIV, syphilis and hepatitis B virus (columns), the 2030 aspirational targets, the EMTCT impact targets and the process/programmatic targets (rows).",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-349550/blocks/prose-page-018",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 18",
      "pageStart": 18,
      "pageEnd": 18,
      "target": "../sections/page-018.md",
      "narrative": null,
      "content": "Changes, clarifications and new guidance in this third version address the following topics areas:\n1.\t\n\u0007inclusion of validation criteria and processes for EMTCT of HBV (section 3.1.3), including \ncriteria for the recognition of progress in countries with a high burden of HBV (PTE) (section 5);\n2.\t\n\u0007revision of laboratory quality standards, including external quality assurance (EQA) for \nvalidation (section 4.2);\n3.\t\n\u0007expansion of guidance on selection of low-performing subnational administrative units and \ninclusion of subpopulations with the lowest coverage or access to services (section 4.3.",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Lists the changes in the third version of the guidance, such as adding HBV validation criteria and Path to Elimination recognition, revising laboratory quality standards and expanding guidance on low-performing subnational units. It ends by expressing WHO's hope that the guidance will speed progress.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-349550/blocks/prose-page-019",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 19",
      "pageStart": 19,
      "pageEnd": 19,
      "target": "../sections/page-019.md",
      "narrative": null,
      "content": "1.1. \u0007Mother-to-child transmission in the HIV, syphilis and HBV \nepidemics\nMother-to-child transmission (MTCT), or “vertical transmission”, is a significant contributor to \nthe HIV pandemic, accounting for 9% of new infections globally in 2017 (15). The Joint United \nNations Programme on HIV/AIDS (UNAIDS) reported that, globally, in 2020 an estimated 150 000 \nchildren newly acquired HIV, and an estimated 1.8 million children were living with HIV (16, 17). \nAlthough this is still a large number of new infections, at the peak of the HIV epidemic in 2000 \nthere were close to 470 000 children acqu",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Describes the contribution of vertical transmission to the HIV epidemic, with UNAIDS estimates of new child infections in 2020 compared with the 2000 peak. It notes that the guidance also applies to trans and gender diverse people who can become pregnant.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-349550/blocks/prose-page-020",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 20",
      "pageStart": 20,
      "pageEnd": 20,
      "target": "../sections/page-020.md",
      "narrative": null,
      "content": "2\nCriteria and processes for validation: EMTCT of HIV, Syphilis and Hepatitis B virus\n•\t universal and equitable access to HTS for pregnant and breastfeeding women; \n•\t initiation of lifelong triple antiretroviral therapy (ART) for pregnant women living with HIV, \nwith support for adherence;\n•\t retention in care and viral suppression for pregnant and postpartum women and girls living with HIV; \n•\t safe delivery practices; \n•\t optimal infant-feeding practices;\n•\t access to postnatal antiretroviral (ARV) prophylaxis for HIV-exposed infants; and \n•\t access to HTS for early infant diagnosis (EID)",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Lists key interventions for preventing vertical HIV transmission, then describes the burden of congenital syphilis and of HBV, noting that most chronic HBV infections are acquired in childhood.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-349550/blocks/prose-page-021",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 21",
      "pageStart": 21,
      "pageEnd": 21,
      "target": "../sections/page-021.md",
      "narrative": null,
      "content": "1. Introduction\nthis leads to chronic disease much less often. WHO recommends universal immunization of infants \nwith at least three doses of the hepatitis B vaccine and timely hepatitis B birth dose (HepB-BD) \nvaccination (as soon as possible after birth, preferably within 24 hours) (27). \n1.2. \u0007Triple elimination of mother-to-child transmission and its \nvalidation \nIn public health elimination is generally defined as reduction to zero of the incidence of a disease or \ninfection in a defined geographical area (28). However, because HIV, syphilis and HBV remain public \nhealth issues and preven",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Notes WHO's recommendation for hepatitis B birth dose and infant vaccination, then explains how elimination of vertical transmission is defined and validated as a public health problem. It also describes regional frameworks for triple elimination, such as in the Western Pacific.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-349550/blocks/prose-page-022",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 22",
      "pageStart": 22,
      "pageEnd": 22,
      "target": "../sections/page-022.md",
      "narrative": null,
      "content": "4\nCriteria and processes for validation: EMTCT of HIV, Syphilis and Hepatitis B virus\n“Validation” is a term used to attest that a country has successfully met the criteria for EMTCT of \nHIV and/or syphilis and/or HBV. A unique consideration for validation of EMTCT is that elimination \nmust be achieved while protecting and respecting human rights. It must also include the meaningful \ninvolvement of women, particularly those living with HIV or HBV, as well as affected communities \nin all interventions, including planning and designing programmes, implementation and monitoring \nand evaluation (M",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Defines validation as confirmation that a country has met EMTCT criteria while protecting human rights and involving women living with HIV or HBV. It outlines the history of earlier editions of the guidance.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-349550/blocks/prose-page-023",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 23",
      "pageStart": 23,
      "pageEnd": 23,
      "target": "../sections/page-023.md",
      "narrative": null,
      "content": "Box 1.2. What’s new in the third version\nThis third version includes changes, clarifications and new guidance on criteria and \nprocesses for validation, including the following: \n1.\t inclusion of validation criteria and processes for EMTCT of HBV (section 3.1.3), \nincluding criteria for the recognition of progress in countries with a high burden of \nHBV (PTE) (section 5);\n2.\t revision of laboratory quality standards, including external quality assurance (EQA) for \nvalidation (section 4.2);\n3.\t expansion of guidance on selection of low-performing subnational administrative \nunits and inclusion",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "A box summarising what is new in the third version, including HBV criteria, laboratory standards and subnational selection, and describing the Path to Elimination category for high-burden countries.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-349550/blocks/prose-page-024",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 24",
      "pageStart": 24,
      "pageEnd": 24,
      "target": "../sections/page-024.md",
      "narrative": null,
      "content": "6\nCriteria and processes for validation: EMTCT of HIV, Syphilis and Hepatitis B virus\nAlso revised in the second edition were the (i) criteria for evaluation of human rights, gender \nequality and community engagement, (ii) surveillance case definition of CS, which was expanded, \n(iii) maintenance of validation requirements and (iv) guidance on special circumstances and \nspecial populations.\nThis third version now moves to triple elimination by including HBV. The key changes include \nclarifications and new guidance on inclusion of validation criteria for EMTCT of HBV, details \non maintenance of",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Recaps revisions made in the second edition and explains that the third version adds HBV for triple elimination, noting Botswana as the first country recognised on the Path to Elimination.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-349550/blocks/prose-page-025",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 25",
      "pageStart": 25,
      "pageEnd": 25,
      "target": "../sections/page-025.md",
      "narrative": null,
      "content": "2.1. \u0007Qualifying requirements for EMTCT of HIV, syphilis and HBV\nBefore initiating the validation process, countries should be confident that they can meet the global \nminimum criteria listed below. They are advised to complete the Checklist for country preliminary \nassessment of EMTCT and Path to Elimination criteria (34) (Web Annex A), which is currently \nbeing updated to include EMTCT of HBV. Any country that feels it has met the qualifying global \nrequirements, as well as any additional regional requirements, is encouraged to apply for validation.\n[1]\tNational-level evidence of achievement",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Sets out the qualifying requirements countries should meet before applying for validation, including national-level evidence of meeting targets, and recommends a preliminary self-assessment checklist.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-349550/blocks/prose-page-026",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 26",
      "pageStart": 26,
      "pageEnd": 26,
      "target": "../sections/page-026.md",
      "narrative": null,
      "content": "8\nCriteria and processes for validation: EMTCT of HIV, Syphilis and Hepatitis B virus\n[3]\tExistence of an adequate national monitoring and surveillance system that can capture process \ndata from the whole health sector, comprising both the public and non-public health sectors, \nand can detect a majority of the cases of MTCT of HIV, syphilis and HBV. Data from this system \ncan be used for modelling infant HIV, syphilis and HBV case numbers (see sections 3.1 and 4.1 \nand Annex 2). Monitoring and surveillance must be supported by a strong laboratory system.\n[4]\tValidation criteria must have been",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Continues the qualifying requirements, covering surveillance systems able to detect most vertical infections, meeting criteria in the lowest-performing subnational unit, and programme, human rights and community engagement requirements.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-349550/blocks/prose-page-027",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 27",
      "pageStart": 27,
      "pageEnd": 27,
      "target": "../sections/page-027.md",
      "narrative": null,
      "content": "2. Rationale for standardized criteria and processes for EMTCT of HIV, syphilis and HBV\nThe criteria selected for measuring EMTCT of HIV, syphilis and HBV take into account the \nfollowing aspects of HIV, syphilis and HBV epidemiology and available prevention interventions, \ntreatment and care:\n•\t HIV, syphilis and HBV infection can very often be asymptomatic in adults and infants or young \nchildren, meaning that detection is frequently delayed, and it depends on the initiative of \nthe individual and the capacity of the health system to promote and facilitate access to and \nutilization of testi",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Explains the epidemiological and programme considerations behind the validation criteria, such as frequent asymptomatic infection, the importance of testing and treatment in pregnancy, infant HBV vaccination and protection of women's rights.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-349550/blocks/prose-page-028",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 28",
      "pageStart": 28,
      "pageEnd": 28,
      "target": "../sections/page-028.md",
      "narrative": null,
      "content": "Table 3.1. \u0007Country options for applications for single, dual or \ntriple validation of EMTCT of HIV, syphilis and HBV\n*\u0007Single validation for HBV is done at the regional level (3). Upon special request from the regional validation secretariat or \ncommittee, single validation for HBV may be reviewed at the global level and will include reporting on HIV and syphilis.\nValidation indicators and targets are used to monitor achievement of EMTCT over a defined \nperiod of time. The processes in place for validation assess the quality and ability of the national \nmonitoring and surveillance systems to",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "A table of country options for single, dual or triple validation, with a note that countries should report data on all three infections even if seeking single or dual validation.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-349550/blocks/table-002",
      "types": [
        "folio-assistant-core:Table",
        "doco:Table"
      ],
      "kind": "table",
      "title": "Table 3.1. Country options for applications for single, dual or triple validation of EMTCT of HIV, syphilis and HBV",
      "pageStart": 28,
      "pageEnd": 28,
      "target": "../tables/table-3-1.csv",
      "narrative": "draft",
      "content": "The table shows, with dots, the combinations of infections (HIV, syphilis, HBV) for which a country may apply for single, dual or triple validation of EMTCT.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-349550/blocks/prose-page-029",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 29",
      "pageStart": 29,
      "pageEnd": 29,
      "target": "../sections/page-029.md",
      "narrative": null,
      "content": "Box 3.1. \u0007Summary of required impact and process targets for \nglobal validation of EMTCT of HIV, syphilis and HBV\nEMTCT IMPACT TARGETS \n(Must be the most recent verified data and must be achieved for at least one year)\n•\t MTCT rate of HIV of <2% in non-breastfeeding populations OR <5% in breastfeeding \npopulations (see section 6.2)\n•\t a population case rate of new paediatric HIV infections due to MTCT of ≤50 cases per \n100 000 live births\n•\t a case rate of CS of ≤50 per 100 000 live births\n•\t hepatitis B surface antigen (HBsAg) prevalence of ≤0.1% in the ≤5-year-old birth cohort \n(and older ch",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "A box summarising the impact and process targets required for global validation of EMTCT of HIV, syphilis and HBV, such as MTCT rates, case rates and HBsAg prevalence thresholds.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-349550/blocks/prose-page-030",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 30",
      "pageStart": 30,
      "pageEnd": 30,
      "target": "../sections/page-030.md",
      "narrative": null,
      "content": "12\nCriteria and processes for validation: EMTCT of HIV, Syphilis and Hepatitis B virus\n3.1. \u0007Impact indicators and targets for validation of EMTCT \n3.1.1 Impact indicators and targets for validation of EMTCT of HIV\nPrior to submission of the application for validation, countries are required to have achieved and \nmaintained for at least one year both of the following impact targets for validating EMTCT of HIV:\n•\t an HIV MTCT rate of <5% (breastfeeding populations) OR <2% (non-breastfeeding \npopulations) and\n•\t a population case rate of new paediatric HIV infections due to MTCT of ≤50 per 100 0",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Sets out the two impact targets for validating EMTCT of HIV, an MTCT rate below 5% or 2% and 50 or fewer paediatric cases per 100 000 live births, and describes recommended infant testing schedules.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-349550/blocks/prose-page-031",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 31",
      "pageStart": 31,
      "pageEnd": 31,
      "target": "../sections/page-031.md",
      "narrative": null,
      "content": "The MTCT rate measures vertical transmission (that is, the percentage of vertical infections among births to \nwomen living with HIV) and specifically measures the impact of treatment programmes for preventing vertical \ninfections. The MTCT rate is closely related to the case rate but does not capture all of the interventions required \nto reach EMTCT (Box 3.3).\nWith effective interventions and a high level of maternal treatment coverage, the MTCT rate of HIV can be reduced to \nlevels below 5% in breastfeeding settings and below 2% in non-breastfeeding settings. Therefore, in countries where \nmo",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Explains the HIV MTCT rate and how it relates to the case rate, giving a formula for calculating the case rate from maternal prevalence and MTCT rate.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-349550/blocks/prose-page-032",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 32",
      "pageStart": 32,
      "pageEnd": 32,
      "target": "../sections/page-032.md",
      "narrative": null,
      "content": "14\nCriteria and processes for validation: EMTCT of HIV, Syphilis and Hepatitis B virus\nBox 3.3. \u0007Rationale for use of a case rate of new paediatric \nHIV infections due to vertical transmission \nThe use of a case rate as a standard metric has three advantages:\n1.\t Presenting the case rate as per 100 000 births allows for a measure that is comparable \nacross different country population sizes.\n2.\t It considers maternal seroprevalence and reflects both reduction in the number of \npregnant women living with HIV (through primary prevention of HIV and reducing \nunintended pregnancies among women wit",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "A box on the rationale for using a case rate of new paediatric HIV infections, listing its advantages for comparability and for reflecting prevention efforts. It notes that process indicators should cover all pregnant women living with HIV, including migrants and key populations.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-349550/blocks/prose-page-033",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 33",
      "pageStart": 33,
      "pageEnd": 33,
      "target": "../sections/page-033.md",
      "narrative": null,
      "content": "HIV transmission and case rates derived from studies (including household surveys) should be carefully \nreviewed to ensure that the following limitations do not apply:\n•\t They miss women outside of the PMTCT programme.\n•\t They miss vertical infections due to a woman seroconverting during pregnancy or breastfeeding.\n•\t They miss children who died between birth and the study reference period.\n•\t They miss mother–infant pairs who are lost to follow-up. \n•\t They determine the rate before the end of breastfeeding.\nUsing modelled estimates of population level HIV case rates and MTCT rates can addres",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Lists limitations of HIV vertical transmission and case rates drawn from studies and household surveys, such as missing women outside PMTCT programmes, maternal seroconversion during pregnancy or breastfeeding, early child deaths and loss to follow-up. It recommends modelled estimates as a remedy, noting their weaker reliability in low-prevalence concentrated epidemics, and begins explaining how the Spectrum model accounts for breastfeeding duration and maternal treatment timing.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-349550/blocks/prose-page-034",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 34",
      "pageStart": 34,
      "pageEnd": 34,
      "target": "../sections/page-034.md",
      "narrative": null,
      "content": "16\nCriteria and processes for validation: EMTCT of HIV, Syphilis and Hepatitis B virus\nThe model estimates the number of children acquiring HIV during pregnancy, delivery or \nbreastfeeding. The modelled estimates are captured at the population level and, thus, include \nnew child infections that occurred among women not in the PMTCT programme or not attending \nhealth facilities. The Spectrum model also incorporates seroconversions among mothers during \npregnancy and breastfeeding and, thus, include the resulting vertical transmissions. \nThe model depends heavily on the programme data entered fo",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Explains that Spectrum model estimates capture child HIV infections at population level, including among women outside programmes and those who seroconvert, but depend heavily on accurate data on pregnant women on and retained on ART. It then introduces the surveillance case definition for congenital syphilis, covering stillbirths and live births to inadequately treated seropositive mothers and children with clinical or laboratory evidence of infection.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-349550/blocks/prose-page-035",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 35",
      "pageStart": 35,
      "pageEnd": 35,
      "target": "../sections/page-035.md",
      "narrative": null,
      "content": "Box 3.5. \u0007Rationale for use of the surveillance case \ndefinition for CS\nCS is underreported for many reasons:\n•\t Laboratory and radiographic testing may not be available in some countries or clinical \nsettings.\n•\t Congenital infections that result in spontaneous abortion or stillbirth may not be \nrecognized or reported. Stillbirths are often not delivered in health facilities, and care \nproviders may not realize that stillbirths are the most common adverse pregnancy \noutcome caused by maternal syphilis.\n•\t To make a diagnosis, health care providers must rely on a combination of suggestive \nhis",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Sets out why congenital syphilis is underreported, including limited laboratory and radiographic testing, unrecognized stillbirths and subtle clinical signs that require skilled providers. It explains the reasoning behind the surveillance case definition and the 2015 expert decision to use live births as the denominator, matching the HIV case rate.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-349550/blocks/prose-page-036",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 36",
      "pageStart": 36,
      "pageEnd": 36,
      "target": "../sections/page-036.md",
      "narrative": null,
      "content": "18\nCriteria and processes for validation: EMTCT of HIV, Syphilis and Hepatitis B virus\nLaboratory and radiographic evidence consistent with a diagnosis of CS includes any of the \nfollowing:\na.\t demonstration by dark-field microscopy or fluorescent antibody detection of Treponema \npallidum in the umbilical cord, placenta, nasal discharge or skin lesion material or autopsy \nmaterial of a neonate or stillborn infant;\nb.\t analysis of cerebrospinal fluid (CSF) is reactive for the Venereal Disease Research Laboratory \n(VDRL) test, or elevated CSF cell count or protein;\nc.\t long bone radiographs sugg",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Lists the laboratory and radiographic findings consistent with congenital syphilis, from detection of Treponema pallidum and abnormal cerebrospinal fluid results to suggestive long-bone X-rays and infant serology titres compared with the mother's. It then introduces the WHO Congenital Syphilis Estimation Tool for estimating case rates and planning treatment scale-up where data are poor.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-349550/blocks/figure-vfig-p037",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 37,
      "pageEnd": 37,
      "target": "../figures/vfig-p037.webp",
      "narrative": "draft",
      "content": "A page showing Fig. 3.1, “Key strengths of the WHO Congenital Syphilis Estimation Tool”, a circle with four numbered points: 1 estimates case rates, which is often difficult due to limited or no reporting; 2 evaluates progress needed to assess improvements in ANC-1 testing and treatment coverage targets; 3 estimates the amount of benzathine penicillin needed to treat maternal syphilis and prevent congenital syphilis; 4 demonstrates prevention of congenital syphilis and adverse birth outcomes due to testing and treatment scale-up. Below is Box 3.6, “Management of maternal syphilis”, a text box with WHO treatment recommendations.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-349550/blocks/prose-page-037",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 37",
      "pageStart": 37,
      "pageEnd": 37,
      "target": "../sections/page-037.md",
      "narrative": null,
      "content": "Fig. 3.1. \u0007Key strengths of the WHO Congenital Syphilis \nEstimation Tool\nEstimates case rates\nwhich is often difficult due  \nto limited or no reporting\nDemonstrates prevention\nof congenital syphilis and \nadverse birth outcomes due to \ntesting and treatment scale-up\nEvaluates progress\nwhich is needed to assess \nimprovements in ANC-1 testing \nand treatment coverage targets\nEstimates amount of \nbenzathine penicillin needed\nto treat maternal syphilis and \nprevent congenital syphilis\n1\n2\n4\n3\nBox 3.6. \u0007Management of maternal syphilis\nThe WHO guideline on syphilis screening and treatment for pregnant",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Presents a figure on the main strengths of the WHO Congenital Syphilis Estimation Tool, such as estimating case rates and the benzathine penicillin needed. A box on managing maternal syphilis cites WHO screening and treatment guidance, defines adequate treatment and advises when to evaluate women for reinfection.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-349550/blocks/prose-page-038",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 38",
      "pageStart": 38,
      "pageEnd": 38,
      "target": "../sections/page-038.md",
      "narrative": null,
      "content": "20\nCriteria and processes for validation: EMTCT of HIV, Syphilis and Hepatitis B virus\n3.1.3. \u0007Impact indicators and targets for validation of EMTCT of HBV\nThe goal of programmes for the EMTCT of HBV is to ensure that MTCT of hepatitis B is prevented or \nreduced to a very low level. \nTo achieve validation of EMTCT of HBV, it is necessary to demonstrate the attainment of a set of impact \nand programmatic targets (Boxes 3.7-3.9).\nBox 3.7. \u0007Impact targets for validation of EMTCT of HBV\nCountries that provide universal timely HepB-BD to all neonates should have achieved the \nfollowing impact targe",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Introduces the impact indicators for validating elimination of mother-to-child transmission of hepatitis B, aimed at preventing or minimizing vertical transmission. Countries with universal timely birth-dose vaccination must show HBsAg prevalence of 0.1% or less among children aged five and under, while those using a targeted birth dose must also show a transmission rate of 2% or less.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-349550/blocks/prose-page-039",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 39",
      "pageStart": 39,
      "pageEnd": 39,
      "target": "../sections/page-039.md",
      "narrative": null,
      "content": "Box 3.8. \u0007Rationale for HBV impact targets\nUniversal HepB-BD: HBsAg prevalence ≤0.1% in ≤5-year-olds (and older children  \nin certain circumstances) \nIn the absence of preventive interventions, MTCT of HBV at the time of, or shortly after, \nbirth accounts for most of the global burden of chronic hepatitis B infection (CHB) because \nabout 90% of these perinatal infections lead to chronic infection. The prevalence of HBsAg \nin children ≤5 years old captures new infections from both these vertical transmissions as \nwell as early horizontal transmission routes and is, therefore, a proxy for the tr",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Explains the rationale for using HBsAg prevalence of 0.1% or less in young children as the hepatitis B impact target, since most chronic infections come from perinatal transmission and child prevalence is a proxy for incidence. It allows flexibility in age groups for serosurveys and notes that infants under nine months should not be tested because maternal antibodies cause false negatives.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-349550/blocks/prose-page-040",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 40",
      "pageStart": 40,
      "pageEnd": 40,
      "target": "../sections/page-040.md",
      "narrative": null,
      "content": "22\nCriteria and processes for validation: EMTCT of HIV, Syphilis and Hepatitis B virus\nBox 3.9. \u0007Rationale for HBV impact targets when provision of \nHepB-BD is targeted\nTargeted HepB-BD: HBsAg prevalence ≤0.1% in ≤5-year-olds and MTCT rate of ≤2% \nThe HBV MTCT rate of ≤2% is an additional target for countries that provide targeted timely \nHep B-BD or for countries with a low HBsAg prevalence but where there is still continuing \nhigher prevalence in specific subpopulations of pregnant women with high HBsAg  \n(for example, among indigenous populations or migrant populations from high HBsAg-\nprev",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Explains the additional 2% hepatitis B transmission-rate target for countries using a targeted birth dose or with high-prevalence subpopulations, defining how the rate is calculated. It then introduces process indicators, requiring at least 95% coverage of first antenatal visits and of HIV and syphilis testing among pregnant women for at least two years.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-349550/blocks/prose-page-041",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 41",
      "pageStart": 41,
      "pageEnd": 41,
      "target": "../sections/page-041.md",
      "narrative": null,
      "content": "Box 3.10. \u0007Rationale for maternal HIV and syphilis testing \ncoverage\nNear-universal testing for HIV and syphilis in early pregnancy is necessary to identify \nwomen living with HIV who will benefit from services to prevent MTCT. Testing remains \nan entry point for providing prevention, treatment and care services to women for their \nown health as well as for their families and to prevent MTCT. ANC attendance and testing \ncoverage also measure the strength of MCH services. WHO recommends that all pregnant \nwomen be tested for HIV and syphilis.\nBox 3.11. \u0007Rationale for use of the denominator of p",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Gives the rationale for near-universal HIV and syphilis testing in early pregnancy and for using pregnant women attending antenatal care as the denominator for syphilis testing coverage. It also covers lifelong ART for all women living with HIV and the 95% target for adequate treatment of syphilis-seropositive pregnant women.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-349550/blocks/prose-page-042",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 42",
      "pageStart": 42,
      "pageEnd": 42,
      "target": "../sections/page-042.md",
      "narrative": null,
      "content": "24\nCriteria and processes for validation: EMTCT of HIV, Syphilis and Hepatitis B virus\nBox 3.13. Rationale for syphilis treatment coverage \nWhen treating seropositive pregnant women with at least one dose of intramuscular \nbenzathine penicillin G, 30 days prior to delivery is the minimum time needed to prevent \ntransmission of syphilis to the infant. Ideally, maternal treatment should be given in the first \ntrimester, or as early as possible if the first ANC is delayed. Pregnant women with syphilis \nshould receive treatment according to WHO syphilis treatment guidelines (4, 5).\nNote: Countries",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Explains that syphilis treatment with benzathine penicillin at least 30 days before delivery is needed to prevent infant infection and mentions dual HIV/syphilis rapid tests. It lists the hepatitis B programme targets, including 90% coverage of infant vaccination, timely birth dose, antenatal HBsAg testing and antivirals for high-viral-load mothers.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-349550/blocks/prose-page-043",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 43",
      "pageStart": 43,
      "pageEnd": 43,
      "target": "../sections/page-043.md",
      "narrative": null,
      "content": "Box 3.14. \u0007Rationale for programmatic targets for EMTCT \nof HBV \nThe GHSS on viral hepatitis sets programme coverage targets not only for the most \nimportant preventive interventions (≥90% of infants with three or more doses of \nvaccination and ≥90% of neonates who receive HepB-BD vaccination within 24 hours of \nbirth), but also for diagnosis of 90% of people with HBV and ART for 90% of people with \nHBV who are eligible for treatment especially for countries using targeted timely HepB-BD. \nGlobal models have estimated that achievement of these programme coverage targets in \nvaccination, testin",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Sets out the rationale for hepatitis B programme targets, linking them to the global health sector strategy goals for vaccination, diagnosis and treatment. It explains that 90% coverage of the third infant dose and timely birth dose is expected to achieve the impact targets, and that high antenatal testing coverage matters mainly where the birth dose is targeted.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-349550/blocks/prose-page-044",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 44",
      "pageStart": 44,
      "pageEnd": 44,
      "target": "../sections/page-044.md",
      "narrative": null,
      "content": "26\nCriteria and processes for validation: EMTCT of HIV, Syphilis and Hepatitis B virus\nThe ≥90% coverage of use of antivirals in eligible HBsAg-positive pregnant women with \na high HBV DNA level (>200 000 IU/mL) or hepatitis B e antigen (HBeAg) positivity is an \nadditional indicator based on the 2020 WHO PMTCT recommendations for the use of antivirals \nin HBsAg-positive pregnant women (58).\nThe treatment coverage indicator for HBV is lower than the coverage levels set for \nART and syphilis treatment for HIV and syphilis elimination, respectively, because for \nHBV administration of vaccines (He",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Explains why the 90% antiviral coverage target for eligible HBsAg-positive pregnant women is lower than ART and syphilis treatment targets, as vaccination is the main tool against hepatitis B transmission. It also advises countries to monitor follow-up of exposed infants and notes that regions may add their own non-mandatory indicators.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-349550/blocks/prose-page-045",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 45",
      "pageStart": 45,
      "pageEnd": 45,
      "target": "../sections/page-045.md",
      "narrative": null,
      "content": "4. FOUNDATIONAL REQUIREMENTS \nOF EMTCT VALIDATION\nA standardized approach to providing evidence that demonstrates whether a country has achieved \nEMTCT of HIV, syphilis and HBV across a wide range of epidemiological and programmatic contexts \ngoes beyond achievement of numerical targets. To achieve and maintain elimination, foundational \nrequirements must ensure that quality diagnostics and primary prevention and treatment services \nare available to and accessed by pregnant and postpartum women and that there is a strong health \ninformation system that can effectively capture and monitor cases",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Opens the chapter on foundational requirements for validation, stating that elimination requires quality diagnostics, prevention and treatment services, strong health information systems and respect for human rights, gender equality and community engagement. It begins the data system requirements, such as capturing public and non-public sector data, using standard case definitions and protecting privacy.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-349550/blocks/prose-page-046",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 46",
      "pageStart": 46,
      "pageEnd": 46,
      "target": "../sections/page-046.md",
      "narrative": null,
      "content": "28\nCriteria and processes for validation: EMTCT of HIV, Syphilis and Hepatitis B virus\n•\t make data available for national and subnational administrative units and disaggregation for \nrelevant subpopulations (for example, adolescents, migrants, internally displaced, immigrants, \nnon-citizen residents and indigenous/aboriginal populations).\nSimilar to what is required for most other disease elimination or eradication initiatives, the monitoring \nand surveillance system must be in place for the country to be eligible for validation of elimination or \nbeing on the PTE of HIV, syphilis and HBV. \nD",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Continues the data requirements, calling for subnational and subpopulation disaggregation and country assessment of data completeness, accuracy, consistency and timeliness with a dedicated verification tool. It then turns to laboratory quality, citing ISO 15189 standards and listing key requirements such as quality management, testing algorithms, quality control and external quality assessment.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-349550/blocks/prose-page-047",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 47",
      "pageStart": 47,
      "pageEnd": 47,
      "target": "../sections/page-047.md",
      "narrative": null,
      "content": "Laboratories that contribute data to the surveillance and clinical monitoring systems should:\n[1]\t have a quality management system in place with sufficiently supportive leadership and \ngovernance;\n[2] \tensure the quality of test kits and procedures: that tests are procured, stored and used \naccording to international standards, such as WHO pre-qualification or other regulatory \nequivalent;\n[3]\t ensure the quality of testing: personnel performing the tests who have been trained in \naccordance with nationally recommended algorithms; and\n[4]\t have a laboratory quality assurance mechanism that is",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Sets out what laboratories contributing surveillance and monitoring data must have, namely quality management systems, quality-assured test kits, trained staff and routine quality assurance with external assessment. It describes how the laboratory assessment reviews national testing algorithms and the suitability of the tests chosen.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-349550/blocks/prose-page-048",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 48",
      "pageStart": 48,
      "pageEnd": 48,
      "target": "../sections/page-048.md",
      "narrative": null,
      "content": "30\nCriteria and processes for validation: EMTCT of HIV, Syphilis and Hepatitis B virus\n[3]\t Quality of testing. This is an assessment of staff competence in general through \nprofessional licensure as technologists or appropriate training of other health care workers \nas well as of staff proficiency in performing the tests used.\n[4]\t Laboratory data management. This is an assessment of the laboratory’s information \nmanagement. It focuses specifically on a functional laboratory information system for \nrecording HIV, syphilis and HBV test results and processes for the timely return of results.\n4.",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Describes the remaining laboratory assessment areas, staff competence and laboratory data management, including timely return of results. It then outlines the programme assessment, which reviews national policies and guidelines, services in public and non-public sectors and the performance of low-coverage areas and subpopulations.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-349550/blocks/prose-page-049",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 49",
      "pageStart": 49,
      "pageEnd": 49,
      "target": "../sections/page-049.md",
      "narrative": null,
      "content": "4.4. \u0007Human rights, gender equality and community engagement \nassessment\nA foundational requirement for validation of a country for eliminating vertical transmission  \nof HIV, syphilis and HBV is that the programme and interventions must have been implemented  \nin a manner that is consistent with international, regional and national standards on:\n•\t human rights\n4.3.1. \u0007Assessment of low-performing units and of subpopulations with lowest coverage \nand access to services\nCountries must also provide evidence that, even in the lowest-performing subnational \nadministrative units and among subpopul",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Requires countries to show that services reach even the lowest-performing subnational units and least-served subpopulations. It introduces the requirement that programmes respect international standards on human rights, gender equality and community engagement, and lists assessment steps such as stakeholder interviews and consultations with women using services.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-349550/blocks/prose-page-050",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 50",
      "pageStart": 50,
      "pageEnd": 50,
      "target": "../sections/page-050.md",
      "narrative": null,
      "content": "32\nCriteria and processes for validation: EMTCT of HIV, Syphilis and Hepatitis B virus\n•\t gender equality\n•\t community engagement.\nThe concepts of no one left behind and health equity are central to the WHO global health sector \nstrategies and the broader WHO mission (10-12). Prevention of vertical transmission of HBV, \nnew to this guidance, also values the principles of human rights, gender equality and community \nengagement as fundamental to countries’ ability to effectively address viral hepatitis (64, 65).\n4.4.1. Human rights\nGovernments have an obligation to respect, protect and fulfil hu",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Notes that leaving no one behind and health equity are central to WHO strategies and that the hepatitis B component also adopts human rights, gender and community principles. It describes governments' obligations to respect, protect and fulfil rights, including sexual and reproductive health and rights, in preventing vertical transmission.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-349550/blocks/prose-page-051",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 51",
      "pageStart": 51,
      "pageEnd": 51,
      "target": "../sections/page-051.md",
      "narrative": null,
      "content": "4.4.2. Gender equality\nGender inequality and harmful gender norms and practices in a country can obstruct women’s \nexercise of their rights, including their sexual and reproductive health and rights. In the context of \npreventing vertical transmission of HIV, syphilis and HBV, promoting gender equality is critical, as it \ninfluences the opportunities that women and girls have to access relevant information and services, \nto make autonomous decisions about their sexuality and reproduction and to protect themselves \nfrom STIs (68).\nThe human rights, gender equality and community engagement asses",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Explains how gender inequality and harmful norms can limit women's access to services and autonomy, making gender equality critical to preventing vertical transmission. It describes the assessment tool's markers and its three guiding questions on human rights, gender equality and meaningful engagement of affected women.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-349550/blocks/prose-page-052",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 52",
      "pageStart": 52,
      "pageEnd": 52,
      "target": "../sections/page-052.md",
      "narrative": null,
      "content": "34\nCriteria and processes for validation: EMTCT of HIV, Syphilis and Hepatitis B virus\nThe questions in the tool are qualitative in nature, and the data collection and assessment process \nnecessarily involve consultations with a range of stakeholders, in particular with communities of \nwomen who use the relevant health services. Women who use the programmes know how current \nlaws and policies affect their lives and how these may be put into practice in health care settings, \nand they can both identify challenges as well as propose potential solutions to improve  \nthe programme and help the cou",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Explains that the qualitative assessment requires consultations with stakeholders, especially women who use the services and their networks, who can identify barriers and solutions. It states that assessors must have relevant expertise and involve people from networks of women with HIV alongside experts in human rights and gender.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-349550/blocks/prose-page-053",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 53",
      "pageStart": 53,
      "pageEnd": 53,
      "target": "../sections/page-053.md",
      "narrative": null,
      "content": "Table 4.1. \u0007Key steps for human rights, gender equality and \ncommunity engagement in the validation assessment\nPhase\nRoles and responsibilities\nResponsible entity\n1\nEnsure that validation structures include representatives of networks \nof women living with HIV and HBV.\nNational validation \nstructures\nReview and understand the human rights, community engagement \nand gender equality criteria and tool. \nSelect an independent focal point/consultant with human rights, \ncommunity engagement and gender expertise to support the process.\nIdentify and engage with networks of women living with HIV or \nHB",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "A table setting out the key steps, roles and responsible bodies for the human rights, gender equality and community engagement component of validation, from involving networks of women living with HIV and hepatitis B to holding a dialogue on findings and giving feedback.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-349550/blocks/table-003",
      "types": [
        "folio-assistant-core:Table",
        "doco:Table"
      ],
      "kind": "table",
      "title": "Table 4.1. Key steps for human rights, gender equality and community engagement in the validation assessment",
      "pageStart": 53,
      "pageEnd": 53,
      "target": "../tables/table-4-1.csv",
      "narrative": "draft",
      "content": "The table sets out the key steps for integrating human rights, gender equality and community engagement into the validation assessment, grouped in three phases, with the roles and responsibilities in each phase and the responsible entity (national validation structures or an independent consultant or focal point).",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-349550/blocks/prose-page-054",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 54",
      "pageStart": 54,
      "pageEnd": 54,
      "target": "../sections/page-054.md",
      "narrative": null,
      "content": "Most countries in sub-Saharan Africa have reported a maternal HIV seroprevalence of >2% and a \nmaternal syphilis seroprevalence of >1%. Many countries in East and Southern Africa have maternal \nHIV prevalence of >15%, with some as high as 25%. Even if the MTCT rate of <5% is reached, high HIV \nburden countries have been unable to achieve EMTCT validation due to their elevated HIV prevalence \namong pregnant women, which results in a case rate of new infections in children that remains above \nthe threshold of 50 per 100 000 live births. Similarly, countries with a high syphilis burden (maternal",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Explains that many sub-Saharan African countries cannot reach validation thresholds because high maternal HIV or syphilis prevalence keeps child case rates high even with low transmission rates. It opens the chapter on the path to elimination and lists the prevalence levels that make a country eligible to apply.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-349550/blocks/prose-page-055",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 55",
      "pageStart": 55,
      "pageEnd": 55,
      "target": "../sections/page-055.md",
      "narrative": null,
      "content": "5. \u0007Path to elimination: recognizing progress towards EMTCT in countries with a high burden of HIV, syphilis and HBV\nA country seeking certification on the PTE for HIV and syphilis follows the same procedure as \na country requesting validation of EMTCT. See Chapter 7 and the Governance guidance for the \nvalidation of elimination of mother-to-child transmission of HIV and syphilis (14) for details on  \nthe validation process.\nTable 5.1. \u0007Prevalence requirements, indicators and targets for \ncertification on the PTE of MTCT of HIV, syphilis, and/\nor HBV \nTier\nInfection\nImpact indicators for at \nl",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "States that countries seeking certification on the path to elimination follow the same procedure as for validation. It begins a table of prevalence requirements, impact indicators and programme targets for each tier, with the bronze-tier targets for HIV, syphilis and hepatitis B.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-349550/blocks/table-004",
      "types": [
        "folio-assistant-core:Table",
        "doco:Table"
      ],
      "kind": "table",
      "title": "Table 5.1. Prevalence requirements, indicators and targets for certification on the PTE of MTCT of HIV, syphilis, and/or HBV",
      "pageStart": 55,
      "pageEnd": 56,
      "target": "../tables/table-5-1.csv",
      "narrative": "draft",
      "content": "For each tier of the path to elimination (bronze, silver, gold) and each infection (HIV, syphilis, HBV), the table lists the impact indicators to be met for at least one year and the process/programme indicators to be met for at least two years.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-349550/blocks/prose-page-056",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 56",
      "pageStart": 56,
      "pageEnd": 56,
      "target": "../sections/page-056.md",
      "narrative": null,
      "content": "38\nCriteria and processes for validation: EMTCT of HIV, Syphilis and Hepatitis B virus\nTier\nInfection\nImpact indicators for at least \none year\nProcess/programme indicators for at least two years\nGold tier\nHIV\n•\t \u0007MTCT of HIV rate of <2% in \nnon-breastfeeding populations \nOR <5% in breastfeeding \npopulations\n•\t \u0007A case rate of new paediatric \nHIV infections due to MTCT of \n≤250 cases per 100 000 live \nbirths\n•\t \u0007≥95% ANC coverage (at least one visit) (ANC-1) \n•\t \u0007≥95% HIV testing coverage in pregnant women \n•\t \u0007≥95% ART coverage in pregnant women living with HIV\nSyphilis\n•\t \u0007A case rate of CS o",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Continues the tier table with silver and gold requirements, such as transmission rates below 2% or 5% and paediatric case rates of 250 or fewer per 100,000 live births for the gold tier. It explains that moving up tiers brings a country closer to elimination and that the same principles apply to hepatitis B.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-349550/blocks/prose-page-057",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 57",
      "pageStart": 57,
      "pageEnd": 57,
      "target": "../sections/page-057.md",
      "narrative": null,
      "content": "Table 5.2. \u0007Scenarios of prevalence, indicators and targets  \nfor certification on the PTE of MTCT of HIV\nHIV \nprevalence \nin ANC\nHIV MTCT \nrate\nExpected  \nHIV infant \ncase \nrate/100 000\nApplicable \ntier\nCertification of PTE: \nfor countries with strong \nprogrammes but high ANC \nprevalence, which makes \nit virtually impossible \nto achieve the case rate \ncriterion for validation\n5.0%\n<5.0\n<250\nGold\n7.0%\n<5.0\n<350\nSilver\n9.0%\n<5.0\n<450\nSilver\n11.0%\n<5.0\n<550\nBronze\n15.0%\n<5.0\n<750\nBronze\nValidation of EMTCT: for \ncountries with indicator \nthresholds consistent with \nother public health control \np",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "A table of scenarios linking antenatal HIV prevalence and a transmission rate below 5% to expected infant case rates and the applicable gold, silver or bronze tier, contrasted with full validation thresholds. It then begins describing why many countries face a high hepatitis B burden, including low birth-dose coverage and limited diagnostics.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-349550/blocks/table-005",
      "types": [
        "folio-assistant-core:Table",
        "doco:Table"
      ],
      "kind": "table",
      "title": "Table 5.2. Scenarios of prevalence, indicators and targets for certification on the PTE of MTCT of HIV",
      "pageStart": 57,
      "pageEnd": 57,
      "target": "../tables/table-5-2.csv",
      "narrative": "draft",
      "content": "The table gives scenarios combining HIV prevalence in antenatal care and the HIV MTCT rate, with the expected HIV infant case rate per 100 000 and the applicable tier, separately for certification on the path to elimination and for validation of EMTCT.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-349550/blocks/prose-page-058",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 58",
      "pageStart": 58,
      "pageEnd": 58,
      "target": "../sections/page-058.md",
      "narrative": null,
      "content": "40\nCriteria and processes for validation: EMTCT of HIV, Syphilis and Hepatitis B virus\nBox 5.2. \u0007Rationale for the PTE for HBV\nA key principle is that each tier of the PTE represents a milestone in progress towards \nelimination, where validation of elimination is the ultimate goal. The indicators for PTE \nreflect the critical role of timely HepB-BD and infant vaccination in eliminating MTCT of HBV. \n•\t The bronze level recognizes that a country has implemented a universal timely  \nHepB-BD policy as a first critical step towards EMTCT. \n•\t The silver level of timely HepB-BD coverage of ≥50% rec",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Explains the rationale for the hepatitis B path-to-elimination tiers, with bronze recognizing a universal timely birth-dose policy and higher tiers reflecting coverage milestones. It notes that hepatitis B path-to-elimination recognition is granted only at regional level unless the region asks for global recognition.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-349550/blocks/prose-page-059",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 59",
      "pageStart": 59,
      "pageEnd": 59,
      "target": "../sections/page-059.md",
      "narrative": null,
      "content": "6.1. Special populations\nMost countries face challenges with delivery of health care services to members of key and \nvulnerable populations (including migrants, the internally displaced, immigrants, non-citizen \nresidents, indigenous/aboriginal/First Nation people, members of other mobile populations and \nadolescent girls and young women). Women and their partners belonging to these groups may \nbe at higher risk for HIV, syphilis and HBV and may have relatively poorer access to health care. \nVulnerable populations such as these may be disproportionately represented among pregnant \nwomen with l",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Opens the chapter on special populations and circumstances, noting that migrants, displaced people, indigenous people, adolescent girls and other vulnerable groups may face higher risk and poorer access to antenatal care. It also asks validation reports to describe the infant feeding choices and counselling offered to women living with HIV.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-349550/blocks/prose-page-060",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 60",
      "pageStart": 60,
      "pageEnd": 60,
      "target": "../sections/page-060.md",
      "narrative": null,
      "content": "42\nCriteria and processes for validation: EMTCT of HIV, Syphilis and Hepatitis B virus\nThe national validation report should provide testing data for infants and HIV-exposed children  \nat 6–8 weeks of age and at the end of 18 months (or three months after the end of breastfeeding, \nif longer than 18 months). This schedule should ensure that all possible cases of infants and young \nchildren who acquire HIV are captured and recorded. Countries that are designated as non-\nbreastfeeding must still consider each mother’s choice of infant and young child feeding practice \nand apply the appropriate c",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Specifies infant HIV testing at 6–8 weeks and 18 months, or three months after breastfeeding ends, so that all infections are captured, including in non-breastfeeding settings. It introduces special considerations for small countries and island states, whose data should be verified by regional structures during country missions.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-349550/blocks/prose-page-061",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 61",
      "pageStart": 61,
      "pageEnd": 61,
      "target": "../sections/page-061.md",
      "narrative": null,
      "content": "1.\t Cases determined not to be a failure of the programme or services. If cases are \ndetermined at the regional and global reviews not to result from failure of the programme \nor services, they may be removed from the numerator, with subsequent recalculation of \nscreening and treatment coverage and case rates. Criteria for assessing these cases are  \nas follows. \n•\tAt the discretion of the regional validation committee and, ultimately, the Global Validation \nAdvisory Committee, individual case reports can be reviewed to assess if there are gaps in \nutilization of ANC services, including matern",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Explains that regional and global committees may remove from the numerator infant cases judged not to be programme failures, after reviewing individual case reports. It asks countries with small numbers to provide case studies of exposed infants while preserving anonymity.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-349550/blocks/prose-page-062",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 62",
      "pageStart": 62,
      "pageEnd": 62,
      "target": "../sections/page-062.md",
      "narrative": null,
      "content": "44\nCriteria and processes for validation: EMTCT of HIV, Syphilis and Hepatitis B virus\nHIV MTCT rate for small countries\nPopulation case rate of new infant and young \nchild HIV infections due to MTCT, or infant and \nyoung child case rate for syphilis for small \ncountries\nNumber of \npregnant \nwomen \nwith HIV in \none year\nNumber \nof infant \ncases in \none year\nAnnual \nMTCT rate \n(%)\n4-year \npooled \nMTCT rate \n(%)*\nNumber of \npregnant \nwomen in \none year\nNumber of \ninfant cases \n(HIV or \nsyphilis) in \none year\n1-year \ninfant case \nrate/100 \n000 LB\n4-year \npooled \ninfant case \nrate*\n10\n1\n10%\n2.5\n50",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "A table showing how annual and four-year pooled HIV transmission and infant case rates vary in small countries with few pregnant women or cases. It adds that small countries may use the 2% hepatitis B transmission target, which requires high antenatal testing coverage.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-349550/blocks/table-006",
      "types": [
        "folio-assistant-core:Table",
        "doco:Table"
      ],
      "kind": "table",
      "title": "Table 6.1. Scenarios for HIV MTCT rate and infant case rate of HIV and CS in countries with small populations of pregnant women",
      "pageStart": 62,
      "pageEnd": 62,
      "target": "../tables/table-6-1.csv",
      "narrative": "draft",
      "content": "The table gives worked scenarios for countries with small numbers of pregnant women: the left half shows annual and 4-year pooled HIV MTCT rates for given numbers of pregnant women with HIV and infant cases, and the right half shows 1-year and 4-year pooled infant case rates per 100 000 live births for HIV or syphilis.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-349550/blocks/prose-page-063",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 63",
      "pageStart": 63,
      "pageEnd": 63,
      "target": "../sections/page-063.md",
      "narrative": null,
      "content": "6.4. \u0007Assessing ANC EMTCT service coverage in non-public settings\nIn addition to public sector health services, PMTCT services may be provided by private, \nnongovernmental organizations, faith-based organizations, non-health sector institutions, such \nas health services in correctional facilities and some other non-public entities. Ideally, national \nprogramme monitoring systems should include data from the non-public sectors. Thus, public and \nnon-public data should not be separately reported for achievement of validation criteria. However, \nthere should be evidence in the report that non-pub",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Explains that PMTCT services provided by private, nongovernmental, faith-based and other non-public bodies should be included in national monitoring and reported together with public data. It adds that the programme assessment should compare access, delivery and payment in the non-public sector with the public sector.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-349550/blocks/prose-page-064",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 64",
      "pageStart": 64,
      "pageEnd": 64,
      "target": "../sections/page-064.md",
      "narrative": null,
      "content": "Achieving EMTCT of HIV, syphilis and HBV requires a public health approach based on \nstrengthening the health system to provide the maximum health benefit within the available \nresources while realizing rights to health, participation and gender equality. The validation \napproach sets the standards for quality and accessible interventions and services, with a focus on \nintegration, person-centred care and community engagement within each country’s context.\nBefore initiating the EMTCT validation process (or certification on the PTE), countries should \nbe reasonably confident that they have met",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Opens the chapter on the validation process, emphasizing a public health approach that strengthens health systems while upholding rights, participation and gender equality. It advises countries to confirm they meet minimum criteria before applying and describes the national, regional and global teams that verify country reports using standard assessment tools.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-349550/blocks/prose-page-065",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 65",
      "pageStart": 65,
      "pageEnd": 65,
      "target": "../sections/page-065.md",
      "narrative": null,
      "content": "7. The validation process\n7.1.1. Key partners in validation of EMTCT\nGuiding principles for the process of validation of EMTCT of HIV, syphilis and HBV or progress on \nthe PTE involve aligning the process with relevant national and global strategies and engaging \nrelevant stakeholders in a multisectoral approach. Relevant United Nations partners, such as \nUNAIDS, UNICEF and UNFPA, and other international and national implementing partners that \nare involved in the efforts to achieve EMTCT of HIV, syphilis and HBV may also participate in the \nnational, regional and global validation structures.",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Describes guiding principles and partners in validation, including UN agencies such as UNAIDS, UNICEF and UNFPA, with the health ministry initiating the process. It begins the national-level steps, starting with the ministry's formal request letter sent through the WHO country office.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-349550/blocks/prose-page-066",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 66",
      "pageStart": 66,
      "pageEnd": 66,
      "target": "../sections/page-066.md",
      "narrative": null,
      "content": "48\nCriteria and processes for validation: EMTCT of HIV, Syphilis and Hepatitis B virus\n[2] \tEstablishment of the national validation committee or national validation task force.  \nThe Ministry of Health establishes a national validation committee or task force and, \noptionally, a validation team or working group. \n[3] \tCompletion of the preliminary assessment. The national validation committee, task force, \nteam or working group completes the Checklist for country preliminary assessment of EMTCT \nof HIV, syphilis and HBV and Path to Elimination criteria (34), a tool designed to assist countrie",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Lists further validation steps, including establishing a national validation committee, completing a preliminary assessment checklist and preparing the national report. It then describes regional review and the global review by the Global Validation Advisory Committee, which advises WHO whether the country should be validated or certified.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-349550/blocks/figure-vfig-p067",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 67,
      "pageEnd": 67,
      "target": "../figures/vfig-p067.webp",
      "narrative": "draft",
      "content": "A page showing Fig. 7.1, “Process for validation of EMTCT or PTE certification, including the responsibilities of the health ministry, committees and secretariats at the national, regional and global levels”. Four rows, each with a chevron label, list nine numbered steps: the health ministry requests validation and establishes a national validation committee (steps 1–2); the national committee or task force conducts a preliminary assessment and submits a national report (3–4); the regional validation committee and secretariat review it and submit a regional report (5–7); and the Global Validation Advisory Committee reviews the report, after which the WHO Director-General signs a certificate (8–9).",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-349550/blocks/prose-page-067",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 67",
      "pageStart": 67,
      "pageEnd": 67,
      "target": "../sections/page-067.md",
      "narrative": null,
      "content": "[9] \tOfficial validation. If a country is successfully validated, the Director-General of WHO signs \na certificate recognizing the candidate country’s achievement of validation of EMTCT. The \ncertificate and recommendations for follow-up actions related to the validation review and \nfor maintenance of EMTCT validation status accompany a letter from the Director General \nthat is sent to the WHO Regional Office for transmission to the country.\nFig. 7.1. \u0007Process for validation of EMTCT or PTE certification, \nincluding the responsibilities of the health ministry, \ncommittees and secretariats at t",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Describes the final step, in which the WHO Director-General signs a validation certificate sent with follow-up recommendations through the Regional Office. A figure summarizes the full validation and certification process and the responsibilities at national, regional and global levels.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-349550/blocks/prose-page-068",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 68",
      "pageStart": 68,
      "pageEnd": 68,
      "target": "../sections/page-068.md",
      "narrative": null,
      "content": "The experience of elimination programmes has shown that, to sustain elimination of a disease \nat such a level that it is no longer a public health problem, a country requires a monitoring and \nsurveillance system that can accurately assess intervention coverage and detect the majority of \ncases of MTCT of HIV, syphilis and HBV in a timely manner (including among vulnerable and key \npopulations at risk of acquiring HIV and STIs). For MTCT of HIV, syphilis and HBV, these systems \nprovide ongoing monitoring of the prevalence of disease in pregnant women and the coverage \nand effectiveness of trea",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Opens the chapter on maintaining validation, explaining that sustained elimination needs monitoring and surveillance that track coverage and detect most cases, including in vulnerable groups. A table sets out the time intervals for maintenance reviews by country type and number of infections validated.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-349550/blocks/table-007",
      "types": [
        "folio-assistant-core:Table",
        "doco:Table"
      ],
      "kind": "table",
      "title": "Table 8.1. Time intervals for assessing maintenance of validation",
      "pageStart": 68,
      "pageEnd": 68,
      "target": "../tables/table-8-1.csv",
      "narrative": "draft",
      "content": "The table gives the time interval between maintenance-of-validation reviews for each type of country and validation request (single, dual or triple).",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-349550/blocks/prose-page-069",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 69",
      "pageStart": 69,
      "pageEnd": 69,
      "target": "../sections/page-069.md",
      "narrative": null,
      "content": "8. Maintenance of validation\n8.1. \u0007Process of applying for maintenance of validation\nThe global secretariat maintains a list of countries that have achieved validation and have \nmaintained validation criteria and standards over time. The global secretariat is responsible for \nnotifying regional-level structures of the maintenance review schedules for countries. Countries \nshould prepare reports on maintenance of validation using the maintenance report template in \nWeb Annex J. \nThe national report should be prepared using the national component of the report template \nin Web Annex J and submit",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Describes how countries apply for maintenance of validation, with the global secretariat keeping the list of validated countries and scheduling reviews. Countries prepare reports using a template and should describe programme changes or disruptions, such as those caused by COVID-19 or natural disasters.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-349550/blocks/prose-page-070",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 70",
      "pageStart": 70,
      "pageEnd": 70,
      "target": "../sections/page-070.md",
      "narrative": null,
      "content": "52\nCriteria and processes for validation: EMTCT of HIV, Syphilis and Hepatitis B virus\n[4]  \u0007Responses to recommendations and updates on requests for information made by the Global \nValidation Advisory Committee in the previous review.\nThe regional validation committee reviews the maintenance report to determine whether the \ncountry has maintained validation. The regional validation secretariat then submits the report to \nthe global validation secretariat, accompanied by a separate regional endorsement document for \nmaintaining validation or otherwise, along with relevant comments and recommen",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Describes what countries must submit when reporting on maintaining validation of elimination of mother-to-child transmission (EMTCT) of HIV, syphilis and hepatitis B, and how regional committees review these reports before passing them to the global secretariat. It also explains that after two global maintenance reviews, countries that keep meeting targets may be transferred to regional review, following a vote of the Global Validation Advisory Committee, with the option to revert to global review.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-349550/blocks/prose-page-071",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 71",
      "pageStart": 71,
      "pageEnd": 71,
      "target": "../sections/page-071.md",
      "narrative": null,
      "content": "REFERENCES\n1.   \u0007Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: \nrecommendations for a public health approach. Geneva: World Health Organization; 2021 \n(https://apps.who.int/iris/handle/10665/342899, accessed 8 August 2021).\n2.   \u0007Consolidated guidelines on HIV testing services. Geneva: World Health Organization.  \n(https://www.who.int/publications/i/item/978-92-4-155058-1, accessed 24 March 2021).\n3.   \u0007Interim guidance for country validation of viral hepatitis elimination. Geneva: World Health \nOrganization; 2021 (https://www.who.int/publicati",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "The start of the reference list for the EMTCT validation criteria document, citing mainly WHO guidelines on HIV, hepatitis and syphilis, the 2030 Agenda and the 2021 UN political declaration on HIV and AIDS.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-349550/blocks/prose-page-072",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 72",
      "pageStart": 72,
      "pageEnd": 72,
      "target": "../sections/page-072.md",
      "narrative": null,
      "content": "54\nCriteria and processes for validation: EMTCT of HIV, Syphilis and Hepatitis B virus\n14.   \u0007Governance guidance for the validation of elimination of mother-to-child transmission of HIV \nand syphilis: an overview of structures and responsibilities at national, regional and global \nlevels. Geneva: World Health Organization; 2020 (https://apps.who.int/iris/bitstream/hand\nle/10665/332488/9789240006614-eng.pdf?ua=1, accessed 24 March 2021).\n15.   \u0007Ending AIDS: progress towards the 90–90–90 targets. Global AIDS update 2017. Geneva: \nJoint United Nations Programme on HIV/AIDS (UNAIDS); 2017 (http:/",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Continues the reference list, citing WHO governance guidance for EMTCT validation, UNAIDS global AIDS updates, WHO antiretroviral guidelines, research on maternal syphilis outcomes and a policy brief on dual HIV/syphilis rapid tests.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-349550/blocks/prose-page-073",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 73",
      "pageStart": 73,
      "pageEnd": 73,
      "target": "../sections/page-073.md",
      "narrative": null,
      "content": "26.   \u0007Korenromp EL, Rowley J, Alonso M, Mello MB, Wijesooriya NS, Mahiané SG et al. Global \nburden of maternal and congenital syphilis and associated adverse birth outcomes—\nEstimates for 2016 and progress since 2012. PLOS ONE. 2019;14:e0211720. doi: 10.1371/\njournal.pone.0211720.\n27.   \u0007World Health Organization. Hepatitis B vaccines: WHO position paper, July 2017 \nrecommendations. Wkly Epidemiol Rec. 2017;92:369-92. \n28.   \u0007Dowdle WR. The principles of disease elimination and eradication. Bull World Health Organ. \n1998;76 Suppl 2:22-5. \n29.   \u0007Leprosy (Hansen’s disease) [webpage]. Geneva: W",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Continues the reference list, citing work on congenital syphilis burden, WHO's hepatitis B vaccine position paper, principles of disease elimination and WHO pages on other elimination efforts such as leprosy, onchocerciasis, lymphatic filariasis, dracunculiasis and neonatal tetanus.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-349550/blocks/prose-page-074",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 74",
      "pageStart": 74,
      "pageEnd": 74,
      "target": "../sections/page-074.md",
      "narrative": null,
      "content": "56\nCriteria and processes for validation: EMTCT of HIV, Syphilis and Hepatitis B virus\n40.   \u0007Guideline: updates on HIV and infant feeding: the duration of breastfeeding, and \nsupport from health services to improve feeding practices among mothers living \nwith HIV. Geneva: World Health Organization; 2016 (http://apps.who.int/iris/bitstre\nam/10665/246260/1/9789241549707-eng.pdf, accessed 24 March 2021).\n41.   \u0007Countdown to zero. Global plan towards the elimination of new HIV infections amoung \nchildren by 2015 and keeping their mothers alive. 2011-2015. Geneva: Joint United Nations \nProgramme o",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Continues the reference list, citing WHO guidance on HIV and infant feeding, the UNAIDS Global Plan towards eliminating new HIV infections in children, Spectrum modelling, congenital syphilis strategy and regional hepatitis plans.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-349550/blocks/prose-page-075",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 75",
      "pageStart": 75,
      "pageEnd": 75,
      "target": "../sections/page-075.md",
      "narrative": null,
      "content": "53.   \u0007Global Vaccine Action Plan 2011–2020. Geneva: World Health Organization; 2013 (https://\nwww.who.int/teams/immunization-vaccines-and-biologicals/strategies/global-vaccine-\naction-plan, accessed 26 March 2021).\n54.   \u0007Immunization Agenda 2030: a global strategy to leave no one behind. Geneva: World Health \nOrganization. (https://www.who.int/publications/m/item/immunization-agenda-2030-a-\nglobal-strategy-to-leave-no-one-behind, accessed 30 June 2021).\n55.   \u0007WHO UNICEF Joint Reporting Form: estimates of DPT3 coverage. Geneva: World Health \nOrganization and the United Nations Children’s Fun",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Continues the reference list, citing the Global Vaccine Action Plan, Immunization Agenda 2030, immunization coverage estimates, WHO hepatitis strategic information and prevention guidelines, and international guidelines on HIV and human rights.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-349550/blocks/prose-page-076",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 76",
      "pageStart": 76,
      "pageEnd": 76,
      "target": "../sections/page-076.md",
      "narrative": null,
      "content": "58\nCriteria and processes for validation: EMTCT of HIV, Syphilis and Hepatitis B virus\n67.   \u0007Human rights and health [webpage]. Geneva: World Health Organization; 2017 (https://\nwww.who.int/news-room/fact-sheets/detail/human-rights-and-health, accessed 14 July 2021).\n68.   \u0007Technical Brief. HIV, human rights, and gender equality. Geneva: The Global Fund to Fight \nAIDS, Tuberculosis and Malaria; 2019 (https://www.theglobalfund.org/media/6348/core_\nhivhumanrightsgenderequality_technicalbrief_en.pdf?u=637166001220000000, accessed \n21 September 2021).\n69.   \u0007Promising practices in community engag",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Continues the reference list, citing sources on human rights and gender equality in HIV, community engagement, Gavi's vaccine investment strategy, delivery care coverage and hepatitis B serosurveys.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-349550/blocks/prose-page-077",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 77",
      "pageStart": 77,
      "pageEnd": 77,
      "target": "../sections/page-077.md",
      "narrative": null,
      "content": "80.   \u0007Patel MK, Wannemuehler K, Tairi R, Tutai R, Moturi E, Tabwaia B et al. Progress towards \nachieving hepatitis B control in the Cook Islands, Niue, Tokelau, and Kiribati. Vaccine. \n2016;34:4298-303. doi: 10.1016/j.vaccine.2016.06.083\n81.   \u0007Breakwell L, Anga J, Cooley G, Ropiti L, Gwyn S, Wannemuehler K et al. Seroprevalence \nof chronic hepatitis B virus infection and immunity to measles, rubella, tetanus and \ndiphtheria among schoolchildren aged 6-7 years old in the Solomon Islands, 2016. Vaccine. \n2020;38:4679-86. doi: 10.1016/j.vaccine.2020.05.029\n82.   \u0007Spectrum [website]. Glastonbury",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Ends the reference list with studies on hepatitis B control in Pacific island countries and the Spectrum modelling software.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-349550/blocks/prose-page-078",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 78",
      "pageStart": 78,
      "pageEnd": 78,
      "target": "../sections/page-078.md",
      "narrative": null,
      "content": "A1.1. \u0007Clinical follow-up of infants and young children exposed  \nto HIV\nThe diagnosis of HIV infection in HIV-exposed infants and young children is complicated by the \nvariable sensitivities of assays, ongoing HIV exposure (in utero, intrapartum and postpartum via \nbreastfeeding) and the presence of maternal antibody for up to 12–15 months. For EMTCT, HIV-\nexposed infants and young children should be followed for an appropriate period to determine  \ntheir final infection status.\nANNEXES\nANNEX 1. \u0007CLINICAL FOLLOW-UP \nOF INFANTS AND YOUNG \nCHILDREN EXPOSED TO \nHIV, SYPHILIS OR HBV",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Opens Annex 1 on clinical follow-up of infants and young children exposed to HIV, syphilis or hepatitis B, noting that HIV diagnosis in infants is complicated by assay limits, ongoing exposure and maternal antibodies, so follow-up must continue until final status is known.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-349550/blocks/prose-page-079",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 79",
      "pageStart": 79,
      "pageEnd": 79,
      "target": "../sections/page-079.md",
      "narrative": null,
      "content": "Annex 1. \u0007Clinical follow-up of infants and young children exposed to HIV, syphilis or HBV\nFig. A1. \u0007Simplified infant diagnosis algorithm from WHO’s \nConsolidated guidelines on HIV prevention, testing, \ntreatment, service delivery and monitoring (1)\na The addition to the existing testing algorithm of NAT at birth can be considered.\nb Point-of-care NAT can be used to diagnose HIV infection as well as to confirm positive results.\nc \u0007Start ART without delay. At the same time, retest to confirm infection. As maternal treatment is scaled up and MTCT \ntransmission rates decrease, false-positive res",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Presents WHO's simplified infant HIV diagnosis algorithm, with nucleic acid testing at set ages, prompt antiretroviral therapy with confirmatory retesting, and antibody testing at 18 months or three months after breastfeeding stops. The footnotes explain retesting to avoid false positives, extra testing for never-breastfed children and the continuing risk while breastfeeding lasts.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-349550/blocks/prose-page-080",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 80",
      "pageStart": 80,
      "pageEnd": 80,
      "target": "../sections/page-080.md",
      "narrative": null,
      "content": "62\nCriteria and processes for validation: EMTCT of HIV, Syphilis and Hepatitis B virus\n•   \u0007For HIV-exposed infants, ruling out HIV infection is based on the algorithm in Fig. A1 (1).\n•   \u0007Nucleic acid testing is highly sensitive and specific to identify infection at any age. In infants  \nit should be used to both diagnose and confirm infection (19, 21).\n•   \u0007For HIV-exposed infants, high infant HIV testing coverage at stipulated time points and birth \ncohort monitoring are needed to provide sufficient data on infant outcomes to determine \nthe MTCT and population case rates. While there is no",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Sets out points on ruling out HIV in exposed infants, the role of nucleic acid testing and the need for high infant testing coverage, suggesting over 95% in small, low-prevalence countries and over 80% in high-prevalence ones. It also covers follow-up of syphilis-exposed infants and of hepatitis B-exposed infants, including post-vaccination serological testing as an extra indicator where only targeted birth-dose vaccination is given.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-349550/blocks/prose-page-081",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 81",
      "pageStart": 81,
      "pageEnd": 81,
      "target": "../sections/page-081.md",
      "narrative": null,
      "content": "The WHO policy on hepatitis B vaccination recommends that, where needed, PVST in exposed \ninfants should be carried out at least 1–2 months after administration of the last dose of the \nhepatitis B vaccine series, when the antibody response is greatest (27). Routine PSVT testing for \nimmunity (anti-HBs) is not necessary, as the primary 3-dose series induces protective antibody \nconcentrations in >95% of healthy infants, but can be done in the context of HBV elimination  \nin countries with targeted timely HepB-BD and in countries with low-prevalence settings, where \nit serves as a tool to confi",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Explains WHO advice to do post-vaccination serological testing one to two months after the last hepatitis B dose, noting it is not routinely needed but is useful in elimination contexts. It describes follow-up for infants who are infected, uninfected and protected, or uninfected but non-responders needing revaccination.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-349550/blocks/prose-page-082",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 82",
      "pageStart": 82,
      "pageEnd": 82,
      "target": "../sections/page-082.md",
      "narrative": null,
      "content": "ANNEX 2. \u0007MEASUREMENT OF \nINDICATORS AND TARGETS \nFOR VALIDATION OF EMTCT \nOF HEPATITIS B VIRUS\nA2.1. \u0007Measurement of childhood prevalence of HBsAg in \n≤5-year-olds\nA2.1.1. \u0007Preferred approach: measurement of childhood HBsAg prevalence in \n≤5-year-olds\nThe preferred approach is to directly measure a proxy for chronic HBV incidence (that is, HBsAg \nprevalence in ≤5-year-olds) with national-level biomarker surveys among young children. This is \nthe gold standard recommended by WHO in ≤5-year-olds for monitoring progress towards HBV \ncontrol targets, but it requires large sample sizes in settings",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Opens Annex 2 on measuring indicators for validating elimination of mother-to-child transmission of hepatitis B, recommending national serosurveys of HBsAg prevalence in children aged five and under as the gold standard. It discusses the trade-offs of different age ranges and options to reduce cost, such as targeting higher-prevalence groups or multiphase survey designs.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-349550/blocks/prose-page-083",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 83",
      "pageStart": 83,
      "pageEnd": 83,
      "target": "../sections/page-083.md",
      "narrative": null,
      "content": "Annex 2. \u0007Measurement of indicators and targets for validation of EMTCT of hepatitis B virus\n3) \u0007integrate into existing national surveys for other disease areas (which are often performed using \ndried blood spot testing), such as the Demographic and Health Surveys and AIDS Indicator Surveys. \nFor countries with a small population size, such as the islands in the Pacific, their size need not \nbe a hindrance to conducting a serosurvey to verify elimination, as it may be actually easier to \nconduct the survey and validate elimination. A finite population correction (FPC) factor can be \ncalculate",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Adds the option of integrating hepatitis B testing into existing national surveys and notes that small Pacific island countries can use a finite population correction when sizing serosurveys. It then describes measuring a mother-to-child transmission rate of 2% or less through follow-up of exposed infants in settings with targeted birth-dose vaccination, which requires strong data systems.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-349550/blocks/prose-page-084",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 84",
      "pageStart": 84,
      "pageEnd": 84,
      "target": "../sections/page-084.md",
      "narrative": null,
      "content": "66\nCriteria and processes for validation: EMTCT of HIV, Syphilis and Hepatitis B virus\n1 \u0007Mathematical models employed in the process should be independent and peer reviewed, as the regional validation task force will review inputs, assumptions, analysis \nand outputs in detail during its review of the national validation report. In addition, the models used might vary across countries.\nA2.2. \u0007Using mathematical modelling alongside empirical data  \nto determine attainment of the elimination targets \nModelling is not a substitute for the collection of data, but it can be a tool for using existin",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Explains that mathematical modelling can complement, but not replace, empirical data in judging whether hepatitis B elimination targets are met, and should use independent, peer-reviewed models. It lists uses such as setting country-specific coverage targets, designing biomarker surveys and converting prevalence into incidence estimates, noting standards comparable to Spectrum for HIV are still to be set.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-349550/blocks/prose-page-085",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 85",
      "pageStart": 85,
      "pageEnd": 85,
      "target": "../sections/page-085.md",
      "narrative": null,
      "content": "The following web annexes will be published in 2022.  The current tools can be found at: https://\nwww.who.int/initiatives/triple-elimination-initiative-of-mother-to-child-transmission-of-hiv-\nsyphilis-and-hepatitis-b/validation/process-and-tools.\nWeb Annex A. \u0007Checklist for preliminary assessment of EMTCT \nvalidation\nWeb Annex B. \u0007Congenital syphilis estimation tool\nWeb Annex C. \u0007Initial validation or Path to Elimination report \ntemplate\nWeb Annex D. \u0007Data assessment and verification tool\nWeb Annex E. \u0007Laboratory assessment and verification tool\nWeb Annex F. \u0007Programme assessment and verificat",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Lists the web annexes of the EMTCT validation guidance to be published in 2022, including assessment checklists, report templates, data, laboratory and programme verification tools, and human rights and community engagement tools.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-349550/blocks/prose-page-086",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 86",
      "pageStart": 86,
      "pageEnd": 86,
      "target": "../sections/page-086.md",
      "narrative": null,
      "content": "For more information, contact:\nWorld Health Organization \nDepartment of HIV/AIDS \n20, avenue Appia \n1211 Geneva 27 \nSwitzerland\nE-mail: hiv-aids@who.int\nwww.who.int/hiv",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "The back cover, giving contact details for the WHO Department of HIV/AIDS in Geneva.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    }
  ]
}
